BioMarin Pharmaceutical
Large Cap · Healthcare · Biotechnology
$68.58+$1.59 (+2.37%)
BioMarin Pharmaceutical
Large Cap · Healthcare · Biotechnology
$68.58+$1.59 (+2.37%)
Stock analysis
Get the AI take on BMRN
Track it to unlock the price chart, verdict and what could change it.
- ✓Live price chart
- ✓A clear accumulate, trim or avoid call
Free to track. No card required.
Stock Fundamentals & Key Indicators
52-week range
Low$49.26
High$66.28
Today $68.58
RSI (14)
66.5Neutral
03070100
Overall score
64/100
See the full financial picture
Open the five-year record, valuation checks and Wall Street view behind these scores.
- ✓5 years of revenue, profit and cash flow
- ✓Valuation and balance-sheet checks
- ✓Business and geographic mix
- ✓Analyst targets and recommendation trend
Free for 3 days, then $9/mo. Cancel anytime.
Analyst Rating and Sentiment
Analyst price targets
Lowest
$60
Current price
$68.58
Median target
$86
Highest
$124
LowHigh
Operating Record
Revenue
What's working
- Forward P/E: Investors aren't pricing in much earnings growth, so there's room to be pleasantly surprised.
- Price / FCF: Real cash coming through the door backs up what you're paying.
What to watch
- Debt exceeds cash by $3.3B, increasing balance-sheet pressure, a warning sign.
- EV / EBITDA: The price leans on operating earnings that haven't materialized.
What the market charges
Forward P/E
Favorable · 51% below avg
10.95x
Price / sales
Reasonable · Priced reasonably against its revenue
3.83x
Price / FCF
Strong · Priced well within what its cash flow supports
17.66x
EV / EBITDA
Rich · Operating earnings don't yet support this price
25.36x
How efficiently it compounds
ROIC
Weak · Struggling to earn much on the capital it uses
3.2%
ROE
Needs attention · Unfavorable
1.2%
Debt / equity
Favorable · 0.23 - strong leverage
0.66x
Current ratio
Strong · Comfortable room to cover bills due within a year
2.39x
Peer Comparison
| Company | Mkt cap | P/E | Rev growth | Score |
|---|---|---|---|---|
| $13.04B | 181.6 | +11.2% | 64 |
 | $11.53B | 22.0 | +19.7% | 78 |
 | $4.60B | 13.9 | +13.5% | 77 |
 | $33.87B | 35.4 | +15.5% | 77 |
 | $1.11T | 40.1 | +49.6% | 76 |